Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s):  CPHRF

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.


TSX:CPH - Post by User

Post by nozzpackon Nov 14, 2020 8:12am
776 Views
Post# 31900827

Acquisition Rules for Change of Control Non capital losses

Acquisition Rules for Change of Control Non capital lossesIn Canada, Non-capital losses from a business before the change of control may be carried forward to years after the change of control, but only if the same business is carried on after the change of control with a reasonable expectation of profit, and only to offset income from that business or a similar business.

Similarly, non-capital losses after the change of control from a business can be carried back to years before the change of control only if the same business is carried on with a reasonable expectation of profit, and only to offset income from that business or a similar business.

At a tax rate of 27%, the $211 million in non capital losses held by Cipher will protect previous and forward profits of about $60 million.

Knight have no capital losses for its Canadian Pharma operations.

These would also benefit Bausch for its Canadian operations.

In summary, Ciphers non capital losses are an attractive asset for potential suitors
<< Previous
Bullboard Posts
Next >>